Press release article from our research archive:

Peregrine's Phosphatidylserine-Based Vascular Targeting Agent Technology Presented At Angiogenesis Conference.

TUSTIN, Calif., Sept. 30 /PRNewswire/ -- Peregrine Pharmaceuticals today presented pre-clinical data highlighting phosphatidylserine (PS) as a potential treatment for cancer. The talk, titled "Antibodies to Phospholipids as Vascular Targeting Agents for Cancer Treatment," was presented at the Angiogenesis: New Opportunities & Solutions for Drug Development conference in Cambridge, MA by Peregrine's President and CEO Steven King.

"We are pleased by this opportunity to present pre-clinical data related to our anti-PS antibody clinical candidate for use as a direct anti-cancer agent and as a potential targeting agent for our Vascular Targeting Agent (VTA) technology ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!